Trending
Prev Story
Next Story

Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

The Guardian •
November 18, 2026 • 05:00 AM
3
3 reads 0 reactions

Experts call trial results of medication that slowed cognitive decline by almost a third ‘very promising’

Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer’s disease by almost a third, a global study suggests.

Alzheimer’s is the most common form of dementia, a condition that is forecast to affect 153 million people worldwide by 2050. There is currently no cure.

In a stage three trial spanning 13 countries, including the UK, researchers found the tablet AR1001 slowed decline by 31% in patients with early Alzheimer’s disease not receiving any other treatment.

Experts not involved with the study urged caution but said the results were “exciting” and “very promising” and could signal the arrival of a “totally new treatment” for Alzheimer’s.

The findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston.

AR1001 is a phosphodiesterase-5 inhibitor and from the same family of medicines as Viagra, which is used to treat erectile dysfunction.

The South Korean company AriBio, which makes AR1001, said the drug slowed decline in 604 people taking no other drugs for Alzheimer’s. In a wider group of patients taking other drugs, the tablet did not achieve statistically significant results.

Prof Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, said the results looked “very promising”.

“This drug acts through boosting blood flow and likely also directly stimulating pathways in brain cells that promote learning and memory,” she said.

Dr Sheona Scales, director of research at Alzheimer’s Research UK, said the findings were “very encouraging”, and marked “an important milestone in the search for new Alzheimer’s treatments”.

AR1001 was “especially interesting” because it was an oral drug that took a “different approach” to existing treatments, she said. “Rather than targeting amyloid, it acts on a specific enzyme and influences several other processes involved in brain function.

“The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer’s medications alongside the trial drug. However, this benefit was not significant across the overall trial group.

“Nonetheless, this is an encouraging development in Alzheimer’s research and reinforces the importance of exploring different approaches to tackling this complex disease.”

Dr Richard Oakley, associate director of research and innovation at Alzheimer’s Society, said: “These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms.

“AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.

“Over the year of the trial, this drug was able to effectively slow down people’s decline in memory and thinking by nearly a third, and the side-effects reported were mostly mild to moderate.”

However, the drug did not seem to be as effective for people taking other drugs for Alzheimer’s symptoms, so this needed further investigation, he said.

“AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer’s disease,” said Oakley, adding that people should not take Viagra to try to treat Alzheimer’s.

All the experts called for further trials, and said AR1001 would have to be scrutinised by the scientific community and drug regulatory bodies before it could be prescribed to treat Alzheimer’s.

Prev Swipe Story Next

Same Story from Other Publications

Compare how 5 other independent news outlets reported on this story.

5 Publications
CNN International
2w ago
Patrick Stewart, “Star Trek” and “X-Men” actor, dies aged 86 | CNN

Patrick Stewart, “Star Trek” and “X-Men” actor, dies aged 86 | CNN

The legendary actor died after a “short and poignant journey with Alzheimer’s Disease and Lewy Body Dementia,” a statement read.

#alzheimer #disease
Compare →
NPR News
20h ago
Does locking up a student's cell phone improve test scores? A new study suggests so

Does locking up a student's cell phone improve test scores? A new study suggests so

A new study of school cellphone bans finds they may help students make up for some of the learning they've lost since 2013 – a divergence from earlier study results.

#study #suggests
Compare →
The Australian Financial Review (AFR)
2w ago
Could your head shape be an Alzheimer’s risk? Scientists are looking

Could your head shape be an Alzheimer’s risk? Scientists are looking

Could the geometry of our brains increase the risk of the disease? It’s a provocative question, but one that some scientists are beginning to explore.

#alzheimer
Compare →
Hamro Patro News
1w ago
New Study Suggests Weight Loss and Exercise Can Lead to Type-2 Diabetes Remission in Younger Adults

New Study Suggests Weight Loss and Exercise Can Lead to Type-2 Diabetes Remission in Younger Adults

According to a new study published in the medical field, weight loss and a structured exercise program can be effective, especially for individuals diagnosed with type-2 diabetes at a younger age. ...

#study #suggests
Compare →
BBC News
2w ago
Floods: Building boom in Nepal and India's Uttarakhand puts 300,000 people in path of potential Himalayan disasters, study suggests

Floods: Building boom in Nepal and India's Uttarakhand puts 300,000 people in path of potential Himalayan disasters, study suggests

The construction of tourism facilities, housing, and infrastructure has surged in parts of Nepal and India's Uttarakhand.

#study #suggests
Compare →

Related Stories

Education & Youth
Build #2612